Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa
复制标题
DOI：
10.1038/sj.leu.2402996
复制
发表时间：
2003-08-01
期刊：
影响因子：
11.4
通讯作者：
Apperley, JF
中科院分区：
文献类型：
--
作者：
Marin, D;Marktel, S;Apperley, JF
我们评估了145例慢性粒细胞白血病慢性期患者的临床结果，这些患者符合干扰素-α治疗失败的标准，因此有资格在哈默史密斯医院接受伊马替尼治疗。我们使用单变量和多变量分析，根据治疗3个月后定义的特征制定风险评分。我们确定了低中性粒细胞计数和细胞遗传学反应差（
We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined after treatment for 3 months. We identified a low neutrophil count and poor cytogenetic response (